Global Sepsis Diagnostic Market is expected to grow at a CARG of 8.7% during the forecast period 2020-2027
A new research report published by Fior Markets with the title Sepsis Diagnostic Market By Product (Blood Culture Media, Software, Instruments, Assay Kits & Reagents), Technology (Immunoassays, Microbiology, Biomarkers, Molecular Diagnostics, Flow Cytometry, Microfluidics), Method, Usability, Pathogen, End-User, Region, Global Industry Analysis, Market Size, Share, Growth, Trends, And Forecast 2020 To 2027.
The global Sepsis Diagnostic market is expected to grow from USD 409.79 million in 2019 to USD 798.74 million by 2027, at a CARG of 8.7% during the forecast period 2020-2027
North American region is dominant in terms of revenue and expected to hold the highest market share. The number of cases of sepsis are increasing in the US due to rise in infections which are incurable by antibiotics, rise in geriatric population and high risk of the disease amongst people who have undergone an organ transplant.
However, Asia-Pacific region is dominant in terms of volume due to increase in cases of neonatal umbilical cord sepsis in the countries like India, China and Pakistan.
NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.
DOWNLOAD FREE SAMPLE REPORT: https://www.fiormarkets.com/report-detail/418512/request-sample
The major players of this market are Dickinson & co., Sysmex Corp., BioMerieux, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Bruker Corp., Beckman Coulter Inc., Cepheid Inc., Nanosphere Inc.
Beckman Coulter Inc. announced launch of its SARS-CoV-2 serology test and rams production to deliver over 30 million tests every month.
The product segment includes blood culture media, software, instruments and assay kits & reagents. blood culture media is the leading segment. The technology segment includes immunoassays, microbiology, biomarkers, molecular diagnostics, flow cytometry and microfluidics. Biomarkers have the largest share as they help in early identification of sepsis. The method of sepsis diagnostic are automated diagnosis and conventional diagnosis. automated diagnosis method has the largest share. The usability of sepsis diagnostic are point-of-care testing and laboratory testing. Laboratory testing has the highest share. Based on pathogen, it is divided into fungal and bacterial sepsis. Bacterial sepsis has the largest share. The end-user of sepsis diagnostic includes pathology & reference laboratories and hospitals.
Geriatric and neonatal population is more affective to sepsis and this acts as a driver to the market. Also, rise in the cases of hospital acquired is the driver of this market.
However, lack of skilled physicians and absence of standard protocol are the restrain to the market.
About the report:
The global Sepsis Diagnostic market is analyzed on the basis of value (USD Billion), volume (K Units), export (K Units), and import (K Units). All the segments have been analyzed on global, regional and country basis. The study includes an analysis of more than 30 countries for each segment. The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The study includes porter’s five forces model, attractiveness analysis, raw material analysis, and competitor position grid analysis.
Customization of the Report:
The report can be customized as per client requirements. For further queries, you can contact us on email@example.com or +1-201-465-4211. Our executives will be pleased to understand your requirements and offer you the best-suited reports.
- CDN Newswire